NO965454L - Diatrizoksyester som röntgen kontrastmidler for billeddannelse av blod og lymfesystem - Google Patents

Diatrizoksyester som röntgen kontrastmidler for billeddannelse av blod og lymfesystem

Info

Publication number
NO965454L
NO965454L NO965454A NO965454A NO965454L NO 965454 L NO965454 L NO 965454L NO 965454 A NO965454 A NO 965454A NO 965454 A NO965454 A NO 965454A NO 965454 L NO965454 L NO 965454L
Authority
NO
Norway
Prior art keywords
alkyl
blood
lymphatic system
imaging
agents
Prior art date
Application number
NO965454A
Other languages
English (en)
Other versions
NO965454D0 (no
Inventor
Edward R Bacon
Carl R Illig
Irennegbe K Osifo
Thomas J Caulfield
Original Assignee
Nanosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosystems Llc filed Critical Nanosystems Llc
Publication of NO965454L publication Critical patent/NO965454L/no
Publication of NO965454D0 publication Critical patent/NO965454D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476Particles, beads, capsules, spheres
    • A61K49/0485Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Fremgangsmåte for rontgendiagnostisk billeddannelse av blod og/eller lymfesystem til et pattedyr omfattende administrering av en kontrast effektiv mengde av et partikkelformig iodinert aroyloksyester kontrastmiddel med struktur (I) hvor n er et tall fra 3 til 20; R1 er H, alkyl, fluoralkyl, cykloalkyl, aryl, aralkyl, alkoksyalkyl eller azetamidoalkyl; R^, R3 og R^ er uavhengig H, alkyl, fluoralkyl, alkoksy, aryloksy, halogen, hydroksy, acylamino, acetamidoalkyl, -COO-alkyl, -COO-aryl, -COO-aralkyl, cyano, sulfonyl, karboksamido eller sulfonamido; R^ er H, alkyl, fluoroalkyl, halogen, hydroksy, acylamino, acetamidoalkyl, cyano, sulfonyl, karboksamido eller sulfonamido; R*> og R? er uavhengig alkyl, cykloalkyl, aryl eller aralkyl; og R& og R^ er uavhengig H eller -COR^, er beskrevet. Nye iodinerte aroyloksyesterkontrastmidler med ovennevnte struktur hvor n er et tall fra 5 til 20, røntgenkontrast sammensetninger som omfatter slike midler, og fremgangsmåter for røntgendiagnostiserende billeddannelse ved anvendelse av slike midler er også beskrevet.
NO965454A 1994-06-24 1996-12-18 Diatrizoksy ester som röntgen kontrastmidler for billeddannelse av blod og lymfesystem NO965454D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/265,550 US5525328A (en) 1994-06-24 1994-06-24 Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
PCT/US1995/007336 WO1996000089A1 (en) 1994-06-24 1995-06-08 Diatrizoxy ester as x-ray contrast agents for imaging the blood pool and lymphatic system

Publications (2)

Publication Number Publication Date
NO965454L true NO965454L (no) 1996-12-18
NO965454D0 NO965454D0 (no) 1996-12-18

Family

ID=23010927

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965454A NO965454D0 (no) 1994-06-24 1996-12-18 Diatrizoksy ester som röntgen kontrastmidler for billeddannelse av blod og lymfesystem

Country Status (9)

Country Link
US (1) US5525328A (no)
EP (1) EP0772457A1 (no)
JP (1) JPH10502082A (no)
AU (1) AU2770395A (no)
CA (1) CA2193389A1 (no)
FI (1) FI965095A0 (no)
IL (1) IL114304A0 (no)
NO (1) NO965454D0 (no)
WO (1) WO1996000089A1 (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510458A (ja) * 1993-06-02 1996-11-05 ブラッコ エッセ.ピ.ア. 沃素化された常磁性キレートおよびそれらの造影剤としての使用法
CA2213638C (en) * 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
WO1998048847A1 (en) * 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
GB9710604D0 (en) * 1997-05-22 1997-07-16 Nycomed Imaging As Contrast media
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
CA2451161A1 (en) * 2001-06-22 2003-01-03 Elan Pharma International, Ltd. Method for high through put screening using a small scale mill or microfluidics
EP1429731B1 (en) * 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
RU2207157C2 (ru) * 2001-09-20 2003-06-27 Оренбургская государственная медицинская академия Способ инъекции лимфатической системы
AU2002334939A1 (en) * 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
WO2003039601A1 (en) * 2001-11-07 2003-05-15 Imcor Pharmaceutical Company Methods for vascular imaging using nanoparticulate contrast agents
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
CA2475092C (en) * 2002-02-04 2012-05-01 Baudax Bio, Inc. Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
ATE539737T1 (de) 2002-04-12 2012-01-15 Alkermes Pharma Ireland Ltd Nanopartikuläre megestrol- formulierungen
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040018242A1 (en) * 2002-05-06 2004-01-29 Elan Pharma International Ltd. Nanoparticulate nystatin formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル,リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
SI1553927T1 (sl) * 2002-09-11 2010-12-31 Elan Pharma Int Ltd Z gelom stabilizirani nanodeläśni sestavki uäśinkovine
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
JP4776233B2 (ja) * 2002-11-12 2011-09-21 エラン ファーマ インターナショナル,リミティド 摩損しにくくかつプルランを含む速崩壊性固形製剤
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
WO2004068405A2 (en) * 2003-01-25 2004-08-12 Oraevsky Alexander A High contrast optoacoustical imaging using nanoparticles
US7390505B2 (en) * 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
JP2007501839A (ja) * 2003-08-08 2007-02-01 エラン ファーマ インターナショナル リミテッド 新規メタキサロン組成物
JP4787165B2 (ja) * 2003-11-05 2011-10-05 エラン ファーマ インターナショナル,リミティド 表面安定剤としてペプチドを有するナノ粒子組成物
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
KR20070118224A (ko) * 2005-01-06 2007-12-14 엘란 파마 인터내셔널 리미티드 나노입자형 칸데사르탄 제제
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
MX2007011502A (es) * 2005-03-16 2007-12-07 Elan Pharma Int Ltd Formulaciones de antagonista del receptor de leucotrieno en nanoparticulas con corticosteroide.
CN101198316A (zh) * 2005-03-17 2008-06-11 伊兰制药国际有限公司 纳米微粒双膦酸盐组合物
WO2006102494A2 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
US7825087B2 (en) * 2005-04-12 2010-11-02 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
KR20080008403A (ko) * 2005-05-10 2008-01-23 엘란 파마 인터내셔널 리미티드 나노입자형 클로피도그렐 제제
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
ES2341996T3 (es) * 2005-06-03 2010-06-30 Elan Pharma International Limited Formulaciones de mesilato de imatinib en forma de manoparticulas.
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
JP2008543862A (ja) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子アゼルニジピン製剤
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US20070104792A1 (en) * 2005-09-13 2007-05-10 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
JP2009538927A (ja) * 2006-05-30 2009-11-12 エラン ファーマ インターナショナル,リミティド ナノ粒子状のポサコナゾール製剤
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル,リミティド ナノ粒子ソラフェニブ製剤
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
MX2010009848A (es) * 2008-03-21 2010-09-30 Elan Pharma Int Ltd Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
US7999134B2 (en) * 2009-07-21 2011-08-16 Ge Healthcare As Crystallization of iodixanol using milling
WO2016178876A2 (en) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EA202193251A1 (ru) 2019-06-05 2022-03-10 Эмори Юниверсити Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL239757A (no) * 1958-06-03
US3144479A (en) * 1958-08-07 1964-08-11 Chemie Linz Ag New iodine-containing benzoic acid esters
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5318768A (en) * 1992-05-01 1994-06-07 Sterling Winthrop Inc. Polymeric x-ray contrast compositions containing an organic crystalline x-ray contrast agent
US5330739A (en) * 1992-12-04 1994-07-19 Sterling Winthrop Inc. Iodinated benzoyl acetals and ketals for x-ray imaging
US5322679A (en) * 1992-12-16 1994-06-21 Sterling Winthrop Inc. Iodinated aroyloxy esters
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5360604A (en) * 1994-04-14 1994-11-01 Sterling Winthrop Inc. X-ray contrast compositions containing an organic crystalline X-ray contrast agent in combination with pharmaceutically acceptable clays

Also Published As

Publication number Publication date
JPH10502082A (ja) 1998-02-24
IL114304A0 (en) 1995-10-31
NO965454D0 (no) 1996-12-18
AU2770395A (en) 1996-01-19
US5525328A (en) 1996-06-11
EP0772457A1 (en) 1997-05-14
FI965095A7 (fi) 1996-12-18
CA2193389A1 (en) 1996-01-04
WO1996000089A1 (en) 1996-01-04
FI965095A0 (fi) 1996-12-18

Similar Documents

Publication Publication Date Title
NO965454L (no) Diatrizoksyester som röntgen kontrastmidler for billeddannelse av blod og lymfesystem
NO934333L (no) Ioderte aroyloksyestere
NO941162L (no) Ioderte aromatiske propandioater
PT73879A (de) 1-carboxyalkanoylindolin-2-carbonsauren verfahren zu ihrer herstellung und pharmazeutische praeparate enthaltend diese verbindungen sowie ihre therapeutische verwendung
NO940804L (no) Imidazolidylmakrolider
ES524532A0 (es) Procedimiento de preparacion de los derivados de la xantina
NO950275L (no) Kombinasjonsbehandling for osteoporose
DE69828196D1 (de) Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen
NO965301L (no) 2,4,6-trijod-5-substituerte-amino-isoftalatestere nyttige som röntgenkontrastmidler for medisinsk diagnostisk billeddannelse
NO872880D0 (no) Fremgangsmaate for fremstilling av difenylpropylamin-derivater.
FI870589A0 (fi) Ny farmaceutisk sammansaettning och foerfarande foer framstaellning av den.
DK192987A (da) Kromoglycinsyrederivater, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat
DK156430C (da) Analogifremgangsmaade til fremstilling af 2-oe2'-hydroxy-3'-(1,1-dimethylpropylamino)-propoxyaa-beta-phenylpropiophenon eller syreadditionssalte deraf
ATE31921T1 (de) Amidine, verfahren zu ihrer herstellung und deren anwendung in der therapie.
FI833075A0 (fi) 2-nitro-1,1-etendiaminer, foerfaranden foer deras framstaellning och deras anvaendning som laekemed
NO934794L (no) Preparater av iodfenoksyalkaner og iodfenyletere for visualisering av mage/tarmkanaler
ATE73449T1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DK0759785T3 (da) Liposomsuspensioner som blodkontrastmidler
NO965302L (no) Alfa-cykloalkyl, aryl og aralkylsubstituerte polyjodinerte aroyloksyforbindelser
ATE73807T1 (de) Neue benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte.
DK199682A (da) Fremgangsmaade til fremstilling af 3-(parasubstituerede)-fenoxy-1-alkylaminopropanol-2-forbindelser eller farmaceutisk acceptable salte deraf
SE8500964L (sv) Aminodiarylsulfoxidderivat, forfarande for framstellning derav och farmaceutiska och pesticidiska kompositioner innehallande desamma
DE69005319D1 (de) 1,8-Benzonaphthyridinderivate und ihre Herstellung.
FI906268A0 (fi) 2-formylbenzylfosfonsyraderivat, deras framstaellning och deras anvaendning vid vaord av sjukdomar foerorsakade av virus.
DK0409999T3 (da) Anvendelse af L-ascorbin-2-phosphat-syre eller et farmaceutisk acceptabelt salt deraf til fremstilling af en skylleopløsning til hindring af skader op intraokulart væv